Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER2 trial of Mim8 prophylaxis in adolescents and adults with hemophilia A
MOH_2021-04-08_009494Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of denecimig in hemophilia A (4 arms), sponsored by Novo Nordisk. Started Dec 2020; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2021-04-08_009494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-08_009494.